SCHEMBL4212903

SCHEMBL4212903

O=C(O)c1ccc(-c2cccc(O)c2)cc1Nc1ccc2c(c1)OCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
FABP3 P05413 1/20 0.49
FABP4 P15090 1/20 0.49
FABP5 Q01469 1/20 0.49
GRIK1 P39086 1/20 0.49
NPC1 O15118 6/20 0.46
RAB9A P51151 5/20 0.46
KLF5 Q13887 2/20 0.46
PAX8 Q06710 1/20 0.46
CNR1 P21554 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
FAAH O00519 1/20 0.43
MAPT P10636 2/20 0.42
HSD17B10 Q99714 1/20 0.42
DHODH Q02127 1/20 0.42
AKR1C3 P42330 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227799 0.91 GRIK1 (0.53) MEN1KMT2AFABP3FABP4FABP5
SCHEMBL4220093 0.88 GRIK1 (0.59) MEN1KMT2AFABP3FABP4FABP5
SCHEMBL4219139 0.83 NPC1 (0.50) MEN1KMT2AFABP3FABP4FABP5
SCHEMBL4222898 0.83 AKR1C3 (0.51) GRIK1MAPK9AKR1C3AKR1C2HCAR2
SCHEMBL4228017 0.80 AKR1C3 (0.54) FABP4GRIK1MAPTAKR1C3AKR1C2
SCHEMBL4218151 0.80 KMT2A (0.52) MEN1KMT2AFABP3FABP4FABP5
SCHEMBL4227637 0.80 RAB9A (0.56) MEN1KMT2AFABP3FABP4FABP5
SCHEMBL13890999 0.79 FABP3 (0.44) KMT2AFABP3FABP4FABP5GRIK1
SCHEMBL4212934 0.79 SIRT2 (0.52) GRIK1MAPK9AKR1C3AKR1C2HCAR2
SCHEMBL4223004 0.78 XDH (0.50) GRIK1MAPTDHODHAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 MEN1 2810/4885KMT2A 2524/4885FABP3 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.